Overview

Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

Status:
RECRUITING

Trial end date:
2029-05-01

Target enrollment:

Participant gender:

Summary

A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease

Phase:

PHASE2

Details

Lead Sponsor:

Yehui Tan

Treatments:

venetoclax